Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.
Susan Buchbinder, MD
Departments of Medicine, Epidemiology and Biostatistics
University of California, San Francisco
Director, Bridge HIV
San Francisco Department of Public Health
San Francisco, California
Jontraye Davis, MHA, PMD Pro
Community Program Manager
North Carolina Central University
Durham, North Carolina
Jerome H. Kim, MD
International Vaccine Institute
Seoul, South Korea
Link to the HIV unmuted series from IAS:
Clinical Care Options (CCO) presents expert faculty discussing the barriers and solutions to expanding PrEP uptake, from a nursing perspective
Dr Michelle Collins-Ogle and Clinical Care Options (CCO): HIV postexposure prophylaxis is recommended following a potential sexual exposure.
Clinical Care Options (CCO): expert commentary on major findings from EPIC-NSW and next steps in PrEP strategies and populationwide HIV prevention efforts
Slides from Dr Jason Schafer and Clinical Care Options (CCO): There are key management considerations for patients initiating LA cabotegravir for PrEP